New combo shows promise for stomach cancer patients with hidden HER2 signal
NCT ID NCT04309578
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study tested whether adding trastuzumab (a targeted therapy) to standard chemotherapy could help people with advanced stomach or gastroesophageal junction cancer. Unlike typical patients, these participants had tumors that tested negative for HER2 in tissue but positive in the blood. The trial enrolled 28 patients and measured how many responded to treatment, as well as how long they lived without the disease worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab (Herceptin) combined with capecitabine and cisplatin chemotherapy
What this could lead to
If successful, this could offer a new treatment option for advanced gastric cancer patients whose tumors are HER2-negative in tissue but show HER2 activity in the blood.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The combination also carries typical chemotherapy side effects like nausea, fatigue, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul, South Korea